低分子肝素钙治疗急性脑梗塞的安全性及有效性

The Efficacy and Safety of Low Molecular Weight Heparin (LMWH) Livaracine on Treating Stroke

目的 观察LMWH治疗ACI的临床疗效。方法 住院的ACI患者随机分为LMWH和SH组 ,观察两组治疗前后神经功能缺损程度及监测活化的部分凝血活酶时间 ,纤维蛋白原含量及血小板计数 ,观察复合终点事件。结果 治疗 7天时神经功能缺损评分 ,两组差异无显著性 ,LMWH组复合终点事件明显低于SH组 ,且出血事件明显少于SH组。结论 LMWH治疗急性脑梗塞安全、有效并发症少。

Objective To compared the efficacy and safety between the low Molecular Weight Heparin (LMWH) - Livaracine and standard heparin (SH) in treating stroke. Methods 54 patients with acute cerebral infarction (ACI) were divided into two groups randomly. The patients in two groups were treated with LMWH and SH separately. All patients took 75mg aspirin daily at the same time. The clinical symptoms, composite events (heart diseases, death, recurrent infarction) and adverse reactions were observed. The neurologic impairment, the activated pactiai thrombopilastin time (APTT), the contents of fibrinogen and platelet count were detected. Results After 7 days treatment, patients' neurologic impairment was not significant between two groups. Composite events were significantly reduced in group LMWH than in group SH. Serious bleeding was very few in group LMWH. Conclusions Hypodermic Liraracine is a safe and effective treatment for acute cerebral infarction.